Product Type: Antibody
Descritpion: The nuclear lamina consists of a two-dimensional matrix of proteins located next to the inner nuclear membrane. The lamin family of proteins make up the matrix and are highly conserved in evolution. During mitosis, the lamina matrix is reversibly disassembled as the lamin proteins are phosphorylated. Lamin proteins are thought to be involved in nuclear stability, chromatin structure and gene expression. Vertebrate lamins consist of two types, A and B. Alternative splicing results in multiple transcript variants.
Research Areas: Cancer, Signal transduction, Tags & Cell Markers
Recommended Dilutions: WB 1:500-1:2000, IHC 1:100-1:300, ELISA 1:10000
Size: 200 uL
Immunogen: Synthesized peptide derived from human Lamin A/C around the non-phosphorylation site of Ser22.
Formulation: PBS with 0.02% sodium azide, 0.5% BSA and 50% glycerol, pH7.4
Purification: Affinity purification
Calculated MW: 74kDa
Tissue Specificity/Positive Control: In the arteries, prelamin-A/C accumulation is not observed in young healthy vessels but is prevalent in medial vascular smooth muscle celle (VSMCs) from aged individuals and in atherosclerotic lesions, where it often colocalizes with senescent and degenerate VSMCs. Prelamin-A/C expression increases with age and disease. In normal aging, the accumulation of prelamin-A/C is caused in part by the down-regulation of ZMPSTE24/FACE1 in response to oxidative stress.
Cellular Localization: Nucleus. Nucleus envelope. Farnesylation of prelamin-A/C facilitates nuclear envelope targeting and subsequent cleaveage by ZMPSTE24/FACE1 to remove the farnesyl group produces mature lamin-A/C, which can then be inserted into the nuclear lamina. EMD is required for proper localization of non-farnesylated prelamin-A/C.
Storage: Store at -20C. Avoid freeze / thaw cycles.